BioLineRx Ltd.
BLRX
$3.22
$0.21797.26%
NASDAQ
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Net Income | -3.19M | -5.82M | 484.00K | -696.00K | -13.88M |
Total Depreciation and Amortization | 1.78M | 840.00K | 476.00K | 897.00K | 647.00K |
Total Amortization of Deferred Charges | 742.00K | -- | -- | -- | 59.00K |
Total Other Non-Cash Items | -7.53M | -1.41M | -5.09M | -3.54M | 3.46M |
Change in Net Operating Assets | -410.00K | -3.43M | -7.20M | -10.77M | 14.71M |
Cash from Operations | -8.61M | -9.83M | -11.33M | -14.11M | 4.99M |
Capital Expenditure | 6.00K | 0.00 | -27.00K | -32.00K | -16.00K |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 11.15M | 10.18M | -8.62M | 16.72M | -20.38M |
Cash from Investing | 11.16M | 10.18M | -8.65M | 16.69M | -20.40M |
Total Debt Issued | 0.00 | 0.00 | 19.22M | -- | -- |
Total Debt Repaid | -12.10M | -1.04M | -909.00K | -894.00K | -863.00K |
Issuance of Common Stock | 10.99M | -- | 5.57M | -- | 12.60M |
Repurchase of Common Stock | -- | -180.00K | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | -1.11M | -1.22M | 23.88M | -894.00K | 11.74M |
Foreign Exchange rate Adjustments | 162.00K | 81.00K | -272.00K | 51.00K | 192.00K |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 1.60M | -787.00K | 3.63M | 1.74M | -3.47M |